ADC Therapeutics SA ADCT
1.30 USD -0.07 (-5.11%)
Regular-session close
1.29 -0.01 -0.77%
After hours · Nov 19, 5:59 PM ET
1.29 Day range 1.41
0.78 52-week range 4.98
- YTD
- -63.17%
- 1 year
- -67.66%
News
zacks.com ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.3 per share a year ago.benzinga.com ADC Therapeutics Q3 Adj. EPS $(0.06) Beats $(0.21) Estimate, Sales $21.716M Beat $18.692M Estimate ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.21) by 71.43 percent. This is a 68.42 percent increase over losses of…
prnewswire.com ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending…
seekingalpha.com ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript
marketbeat.com ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study ADC Therapeutics NYSE: ADCT outlined new lymphoma data and plans for further studies of its cancer drug ZYNLONTA, while reporting preliminary third-quarter sales of approximately $21 million and an…
prnewswire.com ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97…
prnewswire.com ADC Therapeutics to Present at November Investor Conferences LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced…
prnewswire.com ADC Therapeutics Announces New Employee Inducement Grant LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced…
prnewswire.com ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced…benzinga.com ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma In addition, Tanabe Pharma has entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd., for the commercialization of ZYNLONTA in Japan.Recently, encouraging results from the…
prnewswire.com ADC Therapeutics Announces ZYNLONTA® Updates in Japan Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results Tanabe Pharma entered…
prnewswire.com ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements $86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing…
marketwatch.com These beaten-down stocks could bounce back in January, if history is any guide Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
prnewswire.com ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026…
marketbeat.com ADC Therapeutics Q2 Earnings Call Highlights ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment's…
seekingalpha.com ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
zacks.com ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
prnewswire.com ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company…
prnewswire.com ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced…
prnewswire.com ADC Therapeutics Announces New Employee Inducement Grant LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced…
prnewswire.com ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial 100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to…
